July 2000
Worldwide Biotech;Jul2000, Vol. 12 Issue 7, p1
Trade Publication
Reports on the treatment developed by scientists at Hadassah University Hospital and Enzo Biochem Inc. which reversed the side effects of a graft versus host disease in an individual receiving bone marrow stem cell transplantation.


Related Articles

  • Steroid-Responsive Chronic Hepatic Graft-versus-Host Disease without Extrahepatic Graft-versus-Host Disease. Gholson, Charles F.; Yau, Jonathan C.; LeMaistre, Charles F.; Cleary, Karen R. // American Journal of Gastroenterology;Oct1989, Vol. 84 Issue 10, p1306 

    A 29-yr-old woman developed severe, progressive cholestasis 5 months after allogeneic bone marrow transplantation. Extrahepatic graft-versus-host diseases (GVHD) was absent. Skin biopsy was equivocal 2 months after transplant, rash was absent during the period of cholestasis, and...

  • Osiris Sees Prochymal Promise Despite Phase III GvHD Failures. Morrison, Trista // BioWorld Today;9/9/2009, Vol. 20 Issue 173, p1 

    The article reports on the failures of the stem cell product, Prochymal, of Osiris Therapeutics Inc., to meet primary end-points for graft-versus-host disease in its Phase III trials. The product failed to have a significant improvement in lung function in the second phase chronic obstructive...

  • Response as an end point in treatment trials for acute GVHD. Pavletic, S Z // Bone Marrow Transplantation;Feb2012, Vol. 47 Issue 2, p161 

    The author argues on that the studies have provided data that suggest day 28 as a suitable time point in measuring the response to first-line therapy in clinical trials for acute graft versus host disease (GVHD). The author stresses that the studies support the expert panel endorsement of day 28...

  • From bone marrow transplantation to complex biological therapy. Marti, Luciana Cavalheiro; Rizzo, Luiz Vicente // Einstein (16794508);Apr-Jun2011, Vol. 9 Issue 2, p244 

    The major complications after bone marrow transplant are related to opportunistic infections or to graft-versus-host disease. Today, there is a wealth of information associated with bone marrow transplantation and new treatment approaches have been proposed to overcome these complications....

  • Cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Shorr, Ronald I.; Longgo, Walter L.; Oberley, Terry D.; Bozdech, Marek J.; Walker, Duard L.; Shorr, R I; Longo, W L; Oberley, T D; Bozdech, M J; Walker, D L // Annals of Internal Medicine;Sep87, Vol. 107 Issue 3, p351 

    Presents a medical case involving a patient with cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Information on hematuria; Profile of the patient; Treatment administered; Results of the treatment.

  • Osiris Targets GVHD With Stem Cell Therapy.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that Osiris Therapeutics Inc. is moving forward with a Phase III pivotal trial of its mesenchymal stem cell therapy Prochymal following the success of its Phase II trial in the U.S. The Prochymal is believed to be the first-line agent to treat acute graft-versus-host disease...

  • Preventing Graft-Versus-Host Disease: Transplanters Glimpse Hope Beyond Immunosuppressants. McNeil, Caroline // JNCI: Journal of the National Cancer Institute;7/3/2013, Vol. 105 Issue 13, p922 

    This article reports on the success of drug trials and other approaches to preventing graft-versus-host disease (GVHD) in leukemia patients with bone marrow transplants, as of July 2013. Drugs that were successful include the C-C chemokine receptor type 5 (CCR5) antagonist and HIV drug maraviroc...

  • Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Wolff, D; Roessler, V; Steiner, B; Wilhelm, S; Weirich, V; Brenmoehl, J; Leithaeuser, M; Hofmeister, N; Junghanss, C; Casper, J; Hartung, G; Holler, E; Freund, M // Bone Marrow Transplantation;May2005, Vol. 35 Issue 10, p1003 

    Summary:Steroid-resistant acute GVHD (aGVHD) following allogeneic hematopoietic stem cell transplantation (alloHSCT) continues to be associated with a high mortality. We report the results of a phase II study of treatment of steroid-resistant aGVHD with the IL-2 receptor antibody daclizumab...

  • Frequency of CD4+FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Fujioka, T; Tamaki, H; Ikegame, K; Yoshihara, S; Taniguchi, K; Kaida, K; Kato, R; Inoue, T; Nakata, J; Ishii, S; Soma, T; Okada, M; Ogawa, H // Bone Marrow Transplantation;Jun2013, Vol. 48 Issue 6, p859 

    Acute GVHD (aGVHD) is a major obstacle to allogeneic hematopoietic SCT (alloHSCT). Although it is thought that aGVHD is initiated in secondary lymphoid organs at a very early stage of alloHSCT, whether CD4+FOXP3+ regulatory T-cells (Tregs) have an impact on aGVHD development during this period...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics